Predicine today announced a strategic partnership with FMD to help biopharma companies accelerate biomarker-driven clinical trials and concurrent New Drug Application (NDA) submissions in the U.S. and China. The collaboration structure allows for global development of novel oncology therapies for biopharmaceutical companies, including global clinical trial support, regulatory support, and biomarker-driven drug development, and CDx...
March 31 – April 3, 2019 Atlanta, Georgia Details: Exhibition booth #4322 Satellite symposium: Biomarker-driven Precision Oncology | March 31, 2019 Poster Presentations: Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients https://www.abstractsonline.com/pp8/#!/6812/presentation/4859 Combined immunohistochemistry and NGS-based patient profiling for predicting anti-PD-1/PD-L1 therapy...
Q: ONCE SEQUENCING HAS BEEN VALIDATED AS A CLINICAL SOLUTION VIA TRUSTED WORKFLOWS, AND COINCIDING WITH THE TECHNOLOGICAL DEVELOPMENTS DRIVING COSTS LOWER, WE CAN EXPECT ACCELERATED HUMAN GENOME PROFILING FOR CLINICAL DX. HOW SOON, DO YOU THINK, WILL WE SEE ACCELERATED GROWTH AND WHAT CAN WE EXPECT? A: We will see accelerated human genome profiling...
Liquid biopsies are being widely studied as a minimally-invasive means for early detection of cancer, monitoring of disease progression, and guiding treatment decisions. However, recent studies in JAMA Oncology reported the discordance between circulating tumor DNA (ctDNA) assay results from commercial platforms such as Guardant Health and PGD, raising questions and concerns regarding the performance...
October 19-23, 2018 Munich, Germany Poster presentation: Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a phase I/II clinical trial in mCRPC patients https://academic.oup.com/annonc/article/29/suppl_8/mdy269.162/5141769?searchresult=1
Predicine, a molecular insights company, announced today that its CLIA-certified genomic sequencing laboratory in the San Francisco Bay Area has received accreditation from the College of American Pathologists (CAP) for meeting the highest standards in quality, operations, and patient safety. Predicine received CAP accreditation for its Shanghai facility last month. The current dual CAP accreditation...
Predicine, a molecular insights company with business operations in U.S. and China, announced today that the company has received accreditation from the College of American Pathologists (CAP) for its genomic sequencing laboratory in Shanghai, China. This CAP accreditation is based on the satisfactory results of a recent on-site inspection as part of the CAP’s Accreditation...
Predicine and Flagship Biosciences are excited to announce a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s artificial intelligence-enabled cTA® digital pathology platform provides complimentary and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space. IO therapies have changed the way we think about patient selection for...
Predicine and Kintor Pharma today announced that new data on Proxalutamide (GT0918) in a Phase I/II clinical trial (NCT02826772) will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. Metastatic castration resistant prostate cancer (mCRPC) is a complex disease with distinct molecular features in relation to genomic instability and...
